Online inquiry

IVTScrip™ mRNA-Anti-SELP, SEG101(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14714MR)

This product GTTS-WQ14714MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets SELP gene. The antibody can be applied in Sickle Cell Disease (SCD) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_003005.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 6403
UniProt ID P16109
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SELP, SEG101(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ14714MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ76MR IVTScrip™ mRNA-Anti-H1-0, (131)I-chTNT-1/B(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA (131)I-chTNT-1/B
GTTS-WQ3156MR IVTScrip™ mRNA-Anti-O-antigen, AR-101(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AR-101
GTTS-WQ7318MR IVTScrip™ mRNA-Anti-FGFR2, FPA-144(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA FPA-144
GTTS-WQ8368MR IVTScrip™ mRNA-Anti-TACSTD2, aTROP2S7(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA aTROP2S7
GTTS-WQ3314MR IVTScrip™ mRNA-Anti-lukG&lukH, ASN-100(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ASN-100
GTTS-WQ14888MR IVTScrip™ mRNA-Anti-SLC39A6, SGN-LIV1A(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SGN-LIV1A
GTTS-WQ15200MR IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA TA-650
GTTS-WQ2719MR IVTScrip™ mRNA-Anti-CD19&CD3E, AMG103(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG103
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW